Boehringer and Pfizer made significant performances in the outpatient prescription ranking

Published: 2015-02-17 10:54:04

Updated: 2015-02-17 10:54:04

It is found out that Products of BoehringerIngelheim Korea and Pfizer Korea has generated significant performances in the outpatient prescription market last year.

According to the analysis result of the top 30 outpatient prescription expense companies based on the UBIST data, the BoehringerIngelheim Korea’s ‘3 products, Twynsta (generic name: telmisartan/amlodipine)’, ‘Trajenta (generic name:...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.